NQO1 and neoplasm: More importantly, since the NAD(P)H: NQO1 is constitutively overexpressed at levels 5- to 200-fold greater in breast [29], non-small cell lung [28], pancreas [27, 30], and prostate cancer [31] compared with the associated normal tissues, selecting Lapa for tumor-specific H2O2 level amplification seems to hold great promise for enhanced CDT efficacy.